ImmunityBio is expected to report a Q2 2026 loss of $0.09 per share on revenue of $18.50 million, while the current stock price of $7.45 remains significantly below the average analyst price target of $11.50. The primary focus for investors remains the commercial sales trajectory and market penetration of ANKTIVA, the company's FDA-approved IL-15 superagonist for bladder cancer.
Analysts are specifically looking for evidence of accelerated physician adoption and expanded insurance coverage following the drug's second full year on the market. Furthermore, updates regarding the clinical expansion of the ANKTIVA platform into lung and colon cancer indications will be critical for validating the company's long-term valuation.